Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mink Therapeutics Inc

INKT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$11.27

▲ +2.45%

Market Cap $57.51M · Vol 736

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$57.51M

Micro Cap

Div Yield

N/A

EPS Growth

+6.31%

YoY

RSI (14)

58.33

Momentum

Beta

0.47

vs Market

52W High

$18.00

37.39% below

52W Low

$8.55

31.81% above

Volume

736

Avg 2.49K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

39.36%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Mink Therapeutics Inc (INKT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INKT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.92%

-1.23%

+7.23%

+1.90%

YTD

+1.08%

-26.44%

-34.09%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-12,494,260.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-125.20% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+6.31%
Outstanding Shares	5.10M

Technical Indicators

50-Day SMA	$11.35
200-Day SMA	$11.51
RSI (14)	58.33
Beta	0.47
52-Week High	$18.00
52-Week Low	$8.55

Volume Today	736
Avg Daily Volume (30D)	2.49K
Relative Volume	0.30x
Volatility (10D)	48.20
Volatility (30D)	57.02
Free Float	39.36%

Analyst Consensus

BUY

Current Price $11.27

Mean Target $39.00

52W Low$8.55 52W High$18.00

Current

Target

$8.55 $18.00

Current Analyst target

+246.05% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG012J84WM7

ISINUS6036932019

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.